Senthil Damodaran

The University of Texas MD Anderson Cancer Center
Country flagUnited States

Research Interests

ApplyKite TwinLearns as you apply

Make your next move.

Prepare your application

Review drafts before you send them.

Explore related searches

Articles (17)

The hormone receptor (HR)‐positive/human epidermal growth factor receptor 2 (HER2)‐negative breast cancer subtype accounts for most early and metastatic breast cancer (MBC) cases. HR‐positive/HER2‐negative MBC is characterized by a relatively prolonged, although variable, disease course and substantial intertumoral and intratumoral heterogeneity. Although endocrine‐based therapies remain the cornerstone of treatment, nearly all patients eventually develop resistance, which is increasingly addressed with biologically targeted agents and newer‐generation cytotoxic drugs. This review summarizes the current understanding of HR‐positive/HER2‐negative MBC biology, highlighting mechanisms of intrinsic and acquired resistance, including driver genomic alterations that, along with clinical factors, help guide therapeutic choices and sequencing. The authors specify and discuss how genomic and transcriptomic profiling inform treatment selection and how side effects and overall patient experience are considered in decision making. Advances in targeted therapies, such as CDK4/6 (cyclin‐dependent kinase 4/6), PI3K (phosphatidylinositol 3‐kinase), and AKT (protein kinase B) inhibitors, and next‐generation estrogen receptor degraders are reviewed along with the expanding role of antibody–drug conjugates and biomarker‐guided tumor‐agnostic biologic therapies. The authors also explore evolving biologic concepts, including the impact of the tumor microenvironment on resistance and disease progression, and consider the distinct clinical behavior of invasive lobular carcinoma and current approaches. Emerging data from contemporary clinical trials promise to refine clinical and biomarker‐driven algorithms and improve outcomes for patients with HR‐positive/HER2‐negative MBC. Ongoing multi‐omic research and adaptive clinical strategies will be essential to further the application of precision oncology in this most common subtype of MBC. Importantly, patient‐reported outcomes, shared decision making, and real‐world evidence are increasingly useful in formulating comprehensive care plans, guidelines, and policy. The modern treatment landscape features a personalized approach that integrates clinical features, biomarkers, and patient preferences across the disease continuum.

Year:

2026

Purpose: Trastuzumab deruxtecan (T-DXd) is currently approved for treating metastatic breast cancer (MBC) that is HER2 positive [immunohistochemistry (IHC) score of 3+ or in situ hybridization (ISH) positivity] or HER2-low (IHC score of 1+ or IHC 2+/ISH negative), as well as for HER2-positive gastric cancer, HER2-mutant lung cancer, and HER2-overexpressing solid tumors. Given the increasing utilization of T-DXd, we sought to determine how HER2 status might change following T-DXd therapy. Experimental Design: We retrospectively reviewed patients with MBC who received T-DXd at the University of Texas MD Anderson Cancer Center. We included patients with paired pre- and post-treatment biopsies assessed for HER2 status using IHC. Results: We included 41 patients with MBC who received treatment with T-DXd and had paired pre- and post-treatment biopsies assessed for HER2 status using IHC. HER2 loss was observed in 11 patients [32.4% of 34 patients with pre-treatment HER2 expression (1+, 2+, or 3+)] following treatment with T-DXd. In addition to the 11 patients with HER2 loss, another 10 patients (29.4%) had a decrease in HER2 score after treatment with T-DXd. Conclusions: HER2 loss and decrease in HER2 expression are common in patients with MBC receiving treatment with T-DXd. Reevaluation of HER2 status following T-DXd treatment should be considered prior to alternate HER2-targeted therapies that require HER2 overexpression for efficacy.

Year:

2025

Purpose: Intratumoral injection of Clostridium novyi -nontoxic ( C. novyi -NT), lacking alpha-toxin, germinates and subsequently replicates in the tumor hypoxic regions, causing cell lysis and inflammation. This phase Ib study investigated the safety and synergistic effects of pembrolizumab and C. novyi -NT in advanced solid tumors. Patients and Methods: Patients with injectable solid tumors received one intratumoral C. novyi -NT injection (day 8) across four dose cohorts (3 × 10 4 to 100 × 10 4 spores) with pembrolizumab (200 mg intravenously every 3 weeks, day 0–24 months). Sixteen patients were enrolled with a median age of 62.5 years, and the most common tumor types were breast cancer and melanoma. Results: The combination therapy demonstrated a manageable safety profile, with one grade 3 dose-limiting toxicity of abscess formation and the remainder of treatment-related adverse events in ≥10% of patients being grade 1 or 2 injection site reaction (25%), pyrexia (19%), pruritus (13%), leukopenia (13%), and anemia (13%). The maximum tolerated dose was determined to be pembrolizumab intravenously at 200 mg every 3 weeks and a single dose of 100 × 10 4 C. novyi -NT spores intratumorally on day 8. The confirmed overall objective response rate of 25% was observed among four patients with nonkeratinizing undifferentiated nasopharyngeal squamous carcinoma, human papilloma virus–positive squamous cell carcinoma of the base of the tongue, vulvar melanoma, and chordoma. Among these patients, we obtained three partial responses and one complete response. The median duration of the response was 10.93 months, and stable disease was observed in 69% of patients. Conclusions: This study highlights the potential of the C. novyi -NT and pembrolizumab combination as a promising therapeutic strategy for treatment-refractory solid tumors.

Year:

2025

Supplementary Table S1. Planned dose levels of Clostridium novyi-NT given intratumorally in combination with the PD-1 inhibitor, pembrolizumab at 200mg intravenously every 3 weeks (cycle = 21 days).

Year:

2025

Somatic mutations identified by whole exome sequencing. Oncoplot representing the most common somatic mutations assessed by whole exome sequencing (WES) in tumors obtained from patients (n = 23) at the time of diagnosis. Genes with mutations occurring in five or more patients are shown.

Year:

2025

Purpose: Trastuzumab deruxtecan (T-DXd) is currently approved for treating metastatic breast cancer (MBC) that is HER2 positive [immunohistochemistry (IHC) score of 3+ or in situ hybridization (ISH) positivity] or HER2-low (IHC score of 1+ or IHC 2+/ISH negative), as well as for HER2-positive gastric cancer, HER2-mutant lung cancer, and HER2-overexpressing solid tumors. Given the increasing utilization of T-DXd, we sought to determine how HER2 status might change following T-DXd therapy. Experimental Design: We retrospectively reviewed patients with MBC who received T-DXd at the University of Texas MD Anderson Cancer Center. We included patients with paired pre- and post-treatment biopsies assessed for HER2 status using IHC. Results: We included 41 patients with MBC who received treatment with T-DXd and had paired pre- and post-treatment biopsies assessed for HER2 status using IHC. HER2 loss was observed in 11 patients [32.4% of 34 patients with pre-treatment HER2 expression (1+, 2+, or 3+)] following treatment with T-DXd. In addition to the 11 patients with HER2 loss, another 10 patients (29.4%) had a decrease in HER2 score after treatment with T-DXd. Conclusions: HER2 loss and decrease in HER2 expression are common in patients with MBC receiving treatment with T-DXd. Reevaluation of HER2 status following T-DXd treatment should be considered prior to alternate HER2-targeted therapies that require HER2 overexpression for efficacy.

Year:

2025

Supplementary Table 1. Antibodies used for immunohistochemistry. Supplementary Table 2. Additional Antibodies used for immunohistochemistry at Daiichi Sankyo. Supplementary Table 3. Biomarker and clinical history of PDX models. Supplementary Table 4. Treatment/control ratios of treated PDX models. Supplementary Table 5. Event-free survival (time to tumor doubling) of treated PDX models. Supplementary Table 6. Mutations in actionable genes in the BCXs. Supplementary Table 7. Copy number alterations in actionable genes in the BCXs. Supplementary Table 8. Mutations in DNA damage repair genes in the BCXs. Supplementary Table 9. Copy number alterations in DNA damage repair genes in the BCXs. Supplementary Table 10. Expression of SLFN11 by IHC. Supplementary Table 11. RPPA Results-Responder vs Non-responder PDX Models. Supplementary Table 12. Treatment/control ratios of BCX.011-CL control and TROP2 models. Supplementary Table 13. Event-free survival (time to tumor doubling) of BCX.011-CL control and TROP2 models. Supplementary Table 14. RPPA Results-Signaling changes common to the responder models. Red changes are common to responders and non-responders. Supplementary Table 15. RPPA Results- Signaling changes common to the Non-Responder models. Red changes are common to responders and non-responders. Supplementary Table 16. Treatment/control ratios of Dato-DXd and Olaparib combination experiments. Supplementary Table 17. Event-free survival (time to tumor doubling) of of Dato-DXd and Olaparib combination experiments.

Year:

2025

Purpose: Datopotamab deruxtecan (Dato-DXd) is a humanized anti–trophoblast cell-surface antigen-2 (TROP2) IgG1 mAb linked to a potent topoisomerase I inhibitor payload (DXd). Dato-DXd has already shown antitumor activity in breast cancer; however, the determinants of response, including the importance of TROP2 expression, remain unclear. We tested the activity of Dato-DXd in a panel of breast cancer patient-derived xenografts (BCX) varying in TROP2 expression. Experimental Design: The antitumor activity of Dato-DXd and isotype-control-DXd (IgG-DXd) was assessed against 11 BCXs varying in TROP2 expression, 10 representing tumors postneoadjuvant chemotherapy. Pharmacodynamic effects were assessed at 24 and 72 hours. The effects of TROP2 expression on Dato-DXd activity was assessed in vitro and in vivo using viral overexpression in BCX-derived cell lines. Results: Models differed in their sensitivity to both Dato-DXd and IgG-DXd. Dato-DXd (10 mg/kg) led to objective response in 4 (36%) models and statistically significant prolongation of event-free survival in 8 (73%) models, whereas IgG-DXd (10 mg/kg) led to response in 1 (9%) and prolonged event-free survival in 3 (27%) models. TROP2 RNA and protein were significantly higher in Dato-DXd–sensitive models. In isogenic cell lines derived from Dato-DXd–resistant BCXs, overexpression of TROP2 conferred Dato-DXd antitumor activity in vitro and in vivo . Dato-DXd increased γH2AX and phospho-KAP1 in the two Dato-DXd–sensitive BCXs but not in a Dato-DXd–resistant BCX. In Dato-DXd–sensitive models, antitumor activity was enhanced in combination with a PARP inhibitor, olaparib. Conclusions: Dato-DXd is active in breast cancer models. Dato-DXd has TROP2-dependent and -independent mediators of activity; however, high TROP2 expression enhances Dato-DXd antitumor activity.

Year:

2025

Supplementary Figure 1. Comparison of TROP2 membrane expression between patient tumors and matched patient derived xenografts. Supplementary Figure 2. Representative images of TROP2 IHC in the breast cancer xenografts shown in Figure 2. Images represent one of three cores of a TMA assessed, with IHC shown at 20X. Supplementary Figure 3. Genomic alterations in genes associated with DNA damage repair. Supplementary Figure 4 BRCAness in BCX models Supplementary Figure 5. Violin plot of BRCAness signature in responders and non-responders. Supplementary Figure 6. Homologous repair in BCX models Supplementary Figure 7. Antitumor activity of Datopotamab deruxtecan (Dato-DXd) and PARP inhibitor talazoparib Supplementary Figure 8. IHC of TROP2 Supplementary Figure 9. Necrosis analysis Supplementary Figure 10. Internalization assay Supplementary Figure 11. (A) Immunoblotting of TROP2 expression in xenografts of BCX.011CL-control and BCX.011-TROP2. The first two on the left are cell line samples as controls for immunoblotting. The remaining are PDX tumor samples. PDX tumors (treated as shown) were collected on day 25-day 28 of treatment. TROP2 IHC was perform and scored. All BCX.011CL-TROP2 tumors formed TROP2 positive xenograft except for a single tumor that grew back after regressing with the first 10 mg/kg Dato-DXd treatment (B). Supplementary Figure 12. Effect of exogenous TROP2 expression on Dato-DXd sensitivity. Supplementary Figure 13. TROP2 expression in isogenic cell lines Supplementary Figure 14. Conjugated DXd in BCXs Supplementary Figure 15. Additional immunohistochemistry analysis of pharmacodynamic changes associated with Dato-DXd treatment

Year:

2025

Purpose: Epidermal growth factor receptor (EGFR) pathway activation causes chemotherapy resistance, and inhibition of the EGFR pathway sensitizes triple-negative breast cancer (TNBC) cells to chemotherapy in preclinical models. Given the high prevalence of EGFR overexpression in TNBC, we conducted a single-arm phase II study of panitumumab (anti-EGFR monoclonal antibody), carboplatin, and paclitaxel as the second phase of neoadjuvant therapy (NAT) in patients with doxorubicin and cyclophosphamide (AC)–resistant TNBC (NCT02593175). Patients and Methods: Patients with early-stage, AC-resistant TNBC, defined as disease progression or ≤80% reduction in tumor volume after four cycles of AC, were eligible for this study and received panitumumab (2.5 mg/kg i.v., every week × 13), paclitaxel (80 mg/m 2 i.v. every week × 12), and carboplatin (AUC = 4 i.v., every 3 weeks × 4) as the second phase of NAT. A two-stage Gehan-type design was used to detect an improvement in the pathological complete response (pCR)/residual cancer burden class I (RCB-I) rate from 5% to 20%. Whole-exome sequencing was performed on diagnostic tumor biospecimens, where available. Results: From November 3, 2016, through August 23, 2021, 43 patients with AC-resistant TNBC were enrolled. The combined pCR/RCB-I rate was 30.2%. The most common treatment-related adverse events were neutropenia (72%) and anemia (61%), with 7 (16%), 16 (37%), and 8 (19%) patients experiencing grade 4 neutropenia, grade 3 neutropenia, and grade 3 anemia, respectively. No new safety signals were observed. Conclusions: This study met its primary endpoint (pCR/RCB-I = 30.2% vs. 5% in historical controls), suggesting that panitumumab should be evaluated as a component of NAT in patients with chemotherapy-resistant TNBC in a larger, randomized clinical trial. Significance: The epidermal growth factor receptor (EGFR) pathway has been implicated as a driver of chemotherapy resistance in triple-negative breast cancer (TNBC). Here, we evaluate the combination of panitumumab, carboplatin, and paclitaxel as the second phase of neoadjuvant therapy (NAT) in patients with AC-resistant TNBC. This study met its primary efficacy endpoint, and molecular alterations in EGFR pathway genes did not seem to influence response to the study regimen.

Year:

2025

Year:

2025

Year:

2024

Year:

2024

Year:

2024

Year:

2024

Year:

2024

Year:

2024

Collaborators (37)

Carlos Barcenas

Associate Professor

The University of Texas MD Anderson Cancer Center

UNITED STATES
View details

Naoto Ueno

Professor of Medicine

University of Hawai'i Cancer Center

UNITED STATES
View details

Kanwal Raghav

Professor

The University of Texas MD Anderson Cancer Center

UNITED STATES
View details

Aysegul Sahin

Professor

The University of Texas MD Anderson Cancer Center

UNITED STATES
View details

Xiaoping Wang

Assistant Professor

The University of Texas MD Anderson Cancer Center

UNITED STATES
View details

Lauren A. Byers

The University of Texas MD Anderson Cancer Center

UNITED STATES
View details

Jennifer K. Litton

Professor

The University of Texas MD Anderson Cancer Center

UNITED STATES
View details

Akshara Raghavendra

The University of Texas MD Anderson Cancer Center

UNITED STATES
View details

Aung Naing

The University of Texas MD Anderson Cancer Center

UNITED STATES
View details

Apostolia M. Tsimberidou

Professor

The University of Texas MD Anderson Cancer Center

UNITED STATES
View details

Anil Korkut

The University of Texas MD Anderson Cancer Center

UNITED STATES
View details

Jeffrey Chang

The University of Texas Health Science Center at Houston

UNITED STATES
View details

Paula Pohlmann

The University of Texas MD Anderson Cancer Center

UNITED STATES
View details

Gabriel N. Hortobagyi

The University of Texas MD Anderson Cancer Center

UNITED STATES
View details

Khandan Keyomarsi

The University of Texas MD Anderson Cancer Center

UNITED STATES
View details

Anthony P. Conley

Associate Professor

The University of Texas MD Anderson Cancer Center

UNITED STATES
View details

Sarina Piha-Paul

Professor

The University of Texas MD Anderson Cancer Center

UNITED STATES
View details

Bora Lim

Associate Professor

The University of Texas MD Anderson Cancer Center

UNITED STATES
View details

Kelly K Hunt

Chair

The University of Texas MD Anderson Cancer Center

UNITED STATES
View details

Siqing Fu

Professor

The University of Texas MD Anderson Cancer Center

UNITED STATES
View details

Hannah Wingate

The University of Texas MD Anderson Cancer Center

UNITED STATES
View details

Jing Wang

Professor

The University of Texas MD Anderson Cancer Center

UNITED STATES
View details

David S. Hong

The University of Texas MD Anderson Cancer Center

UNITED STATES
View details

Ryan Sun

Assistant Professor

The University of Texas MD Anderson Cancer Center

UNITED STATES
View details

Funda Meric-Bernstam

The University of Texas MD Anderson Cancer Center

UNITED STATES
View details

Elizabeth Mittendorf

Harvard University

UNITED STATES
View details

Banu K. Arun

The University of Texas MD Anderson Cancer Center

UNITED STATES
View details

Rodabe N. Amaria

Assistant Professor

The University of Texas MD Anderson Cancer Center

UNITED STATES
View details

Suzanne Fuqua

Professor

Baylor College of Medicine

UNITED STATES
View details

Alastair M Thompson

Professor of Surgery

Baylor College of Medicine

UNITED STATES
View details

Lei Huo

The University of Texas MD Anderson Cancer Center

UNITED STATES
View details

Mohamed Gouda

The University of Texas MD Anderson Cancer Center

UNITED STATES
View details

Ken Chen

Professor

The University of Texas MD Anderson Cancer Center

UNITED STATES
View details

Khashayarsha Khazaie

Professor and Consultant

Mayo Clinic Arizona

UNITED STATES
View details

Timothy Yap

The University of Texas MD Anderson Cancer Center

UNITED STATES
View details

Maria Gabriela Raso

Assistant Professor

The University of Texas MD Anderson Cancer Center

UNITED STATES
View details

Miral M Patel

The University of Texas MD Anderson Cancer Center

UNITED STATES
View details